Skip to main content

Drug Interaction Report

2 potential interactions and/or warnings found for the following 2 drugs:

Filter by interaction and/or warning

Interactions between your drugs

No drug ⬌ drug interactions were found between the drugs in your list. However, this does not necessarily mean no drug interactions exist. Always consult your healthcare provider.

Drug and food interactions

Minor

zalcitabine food

Applies to: Hivid (zalcitabine)

Zalcitabine bioavailability may be decreased by 14% if taken with meals. The mechanism and clinical significance are unknown.

References

  1. (2001) "Product Information. HIVID (zalcitabine)." Roche Laboratories

Switch to consumer interaction data

Minor

grazoprevir food

Applies to: Zepatier (elbasvir / grazoprevir)

Food does not appear to have clinically significant effects on the pharmacokinetics of elbasvir and grazoprevir. When a single 50 mg-100 mg dose of elbasvir-grazoprevir was administered to healthy study subjects with a high-fat meal (900 kcal; 500 kcal from fat), elbasvir peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 15% and 11%, respectively, while grazoprevir Cmax and AUC increased by 2.8- and 1.5-fold, respectively, compared to administration under fasting conditions. According to the product labeling, elbasvir-grazoprevir may be administered with or without food.

References

  1. (2016) "Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc

Switch to consumer interaction data

Therapeutic duplication warnings

No duplication warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Learn more

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.